VRCA
Verrica
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
VRCA Profile
Verrica Pharmaceuticals Inc.
A dermatology therapeutics company developing medications for skin diseases requiring medical interventions
44 West Gay Street, Suite 400, West Chester, PA 19380
--
Verrica Pharmaceuticals Inc., was incorporated under the laws of the State of Delaware on July 3, 2013. The company is a clinical-stage medical dermatology company dedicated to identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases and meeting significant needs. The company's lead product candidate, VP-102, is a patented drug device combination whose novel plaque hormone topical solution is a widely recognized natural source drug for the treatment of local skin diseases, administered through its single-use precision applicator. The company is initially developing VP-102 for the treatment of molluscum contagiosum or molluscum, a highly contagious, mostly pediatric viral skin disease and common wart. There are currently no products approved by the U.S. Food and Drug Administration or the FDA, and there is no established standard of care for these diseases, resulting in two significant untreated populations with the largest unmet needs in dermatology. In addition to the patent protection they are seeking, VP-102 also has the potential to be the first FDA-approved new product for mollusks and their active pharmaceutical ingredients or APIs, namely New Chemical Entities or NCEs, with many years of generic regulatory exclusivity associated with this designation.